

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: AKS1/21 - Basic Clinical Chemistry - Serum

Deadline: 29.01.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability						Traceability															
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(1) Sodium					51							0									51	50	98%
Samples and groups	[mmol/L]																						
Sample A		155	2,1	1,4	51							0	CRV	155,8	2,4	5%	148	164		51	50	98%	
(2) Indirect ISE		155	2,0	1,3	44	0															44		
(3) Direct ISE		154	2,4	1,6	5	0															5		
Other					2	0															2		
													2x 99										
Sample B		132	1,7	1,3	51							0	CRV	132,5	2,0	5%	125	140		51	50	98%	
(2) Indirect ISE		132	1,5	1,2	44	0															44		
(3) Direct ISE		132	2,4	1,8	5	0															5		
Other					2	0															2		
													2x 99										
(2) Potassium					51							0									51	44	86%
Samples and groups	[mmol/L]																						
Sample A		2,86	0,08	3,0	51							0	CRV	2,753	0,044	7%	2,56	2,95		51	44	86%	
(2) Indirect ISE		2,85	0,07	2,8	44	0															44		
(3) Direct ISE		2,89	0,01	0,51	5	0															5		
Other					2	0															2		
													2x 99										
Sample B		5,77	0,13	2,2	51							0	CRV	5,764	0,086	7%	5,36	6,17		51	50	98%	
(2) Indirect ISE		5,78	0,12	2,1	44	0															44		
(3) Direct ISE		5,70	0,09	1,7	5	0															5		
Other					2	0															2		
													2x 99										
(3) Chloride					51							51	45	88%							0		
Samples and groups	[mmol/L]																						
Sample A		140	2,5	1,8	51		CVP	140	0,46	7%	130	150	51	46	90%						0		
(3) Indirect ISE		140	2,3	1,6	43	0							43										
Other					8	0							8										
							3x 2, 4x 4, 1x 99																
Sample B		113	2,3	2,0	51		CVP	114	0,47	7%	106	122	51	49	96%						0		
(3) Indirect ISE		113	2,2	1,9	43	0							43										
Other					8	0							8										
							3x 2, 4x 4, 1x 99																
(4) Calcium					48							0									48	44	92%
Samples and groups	[mmol/L]																						
Sample A		1,98	0,05	3,0	48							0	CRV	1,941	0,029	8%	1,78	2,1		48	45	94%	
(2) Phot. with o-cresolftalexon		1,98	0,11	5,6	7	0															7		
(3) Photom. with arsenazo III		2,00	0,05	2,5	24	0															24		
(4) Photomet. with NM-BAPTA		1,97	0,05	2,7	17	0															17		
Sample B		2,79	0,06	2,2	48							0	CRV	2,737	0,042	8%	2,51	2,96		48	47	98%	

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: AKS1/21 - Basic Clinical Chemistry - Serum

Deadline: 29.01.2021

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(4) Calcium	[mmol/L]				48							0									48	44	92%
Samples and groups																							
Sample B		2,79	0,06	2,2	48							0	CRV	2,737	0,042	8%	2,51	2,96		48	47	98%	
(2) Phot. with o-cresolftalexon		2,79	0,07	2,7	7	0															7		
(3) Photom. with arsenazo III		2,81	0,06	2,2	24	0															24		
(4) Photomet. with NM-BAPTA		2,78	0,06	2,3	17	0															17		
(5) Inorganic phosphate	[mmol/L]				48							48	45	94%							0		
Samples and groups																							
Sample A		0,932	0,03	3,8	48	CVP	0,933	,0059	10%	0,839	1,03	48	47	98%							0		
(1) UV-molybdate method		0,930	0,03	3,8	45	0						45											
Other					3	0						3											
Sample B		1,34	0,04	3,2	48	^{3x2} CVP	1,34	,0069	10%	1,2	1,48	48	45	94%							0		
(1) UV-molybdate method		1,34	0,04	3,2	45	0						45											
Other					3	0						3											
(6) Iron	[µmol/L]				45							45	43	96%							0		
Samples and groups																							
Sample A		32,3	0,99	3,1	45	CVP	32,6	0,18	15%	27,7	37,5	45	43	96%							0		
(2) Method with ferrozine/ferene		32,3	1,1	3,4	33	0						33											
(4) Method with TPTZ		32,2	0,73	2,3	12	0						12											
Sample B		42,2	1,3	3,0	45	^{3x2} CVP	42,5	0,19	15%	36,1	48,9	45	44	98%							0		
(2) Method with ferrozine/ferene		42,2	1,3	3,1	33	0						33											
(4) Method with TPTZ		42,3	1,3	3,1	12	0						12											
(7) Magnesium	[mmol/L]				48							0									48	46	96%
Samples and groups																							
Sample A		0,984	0,02	2,7	48							0	CRV	0,959	0,015	15%	0,815	1,11		48	47	98%	
(2) Photometry		0,983	0,02	2,9	44	0															44		
Other					4	0															4		
Sample B		1,61	0,04	2,7	48							0	^{4x4} CRV	1,574	0,025	15%	1,33	1,82		48	47	98%	
(2) Photometry		1,60	0,04	2,5	44	0															44		
Other					4	0															4		
(8) Lithium	[mmol/L]				4							0									4	4	100%
Samples and groups																							
Sample A		1,26	0,06	4,9	4							0	CRV	1,309	0,020	12%	1,15	1,47		4	4	100%	
Other					4	0															4		
Sample B		1,22	0,03	3,1	4							0	^{1x3,3x4} CRV	1,244	0,019	12%	1,09	1,4		4	4	100%	
Other					4	0															4		
(9) Total protein	[g/L]				49							0									49	48	98%
Samples and groups																							
Sample A		59,5	1,7	2,8	49							0	CRV	59,44	0,70	9%	54	64,8		49	48	98%	
(1) Biuret		59,5	1,7	2,8	49	0															49		
Sample B		84,9	2,3	2,8	49							0	CRV	86,11	1,0	9%	78,3	93,9		49	49	100%	

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: AKS1/21 - Basic Clinical Chemistry - Serum

Deadline: 29.01.2021

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(9) Total protein	[g/L]				49							0									49	48	98%
Samples and groups																							
Sample B		84,9	2,3	2,8	49							0	CRV	86,11	1,0	9%	78,3	93,9		49	49	100%	
(1) Biuret		84,9	2,3	2,8	49	0															49		
(10) Albumin	[g/L]				48							48	47	98%									0
Samples and groups																							
Sample A		38,9	1,4	3,6	48	CVP	39	0,24	10%	35,1	42,9	48	47	98%									0
(1) BCG		38,9	1,3	3,3	45	0						45											
Other					3	0						3											
Sample B		54,2	1,5	2,8	48	CVP	54,4	0,28	10%	48,9	59,9	48	47	98%									0
(1) BCG		54,3	1,5	2,7	45	0						45											
Other					3	1						3											
(11) Osmolality	[mmol/kg]				12							12	12	100%									0
Samples and groups																							
Sample A		338	6,5	1,9	12	CVP	337	1,6	5%	320	354	12	12	100%									0
(1) Osmometer		338	6,5	1,9	12	0						12											
Sample B		300	4,6	1,5	12	CVP	299	2,1	5%	284	314	12	12	100%									0
(1) Osmometer		300	4,6	1,5	12	0						12											
(12) Lactate	[mmol/L]				19							19	19	100%									0
Samples and groups																							
Sample A		3,88	0,17	4,3	19	CVP	3,94	0,039	15%	3,34	4,54	19	19	100%									0
(3) Photometric enzyme method		3,89	0,15	3,8	12	0						12											
Other					7	0						7											
Sample B		2,93	0,11	3,6	19	CVP	2,96	0,028	15%	2,51	3,41	19	19	100%									0
(3) Photometric enzyme method		2,93	0,07	2,6	12	0						12											
Other					7	0						7											
(13) Bilirubin total	[µmol/L]				51							0											51
Samples and groups																							51
Sample A		31,7	2,7	8,6	51							0	CRV	30,8	1,0	21%	24,3	37,3		51	51	100%	
(2) DCA, DPD		31,7	2,8	8,7	48	0																	48
Other					3	0																	3
Sample B		32,1	2,8	8,7	51							0	CRV	32	0,80	21%	25,2	38,8		51	51	100%	
(2) DCA, DPD		32,1	2,8	8,8	48	0																	48
Other					3	0																	3
(15) Cholesterol	[mmol/L]				48							0											48
Samples and groups																							48
Sample A		3,38	0,14	4,3	48							0											48
(1) Enzyme method CHOD-PAP		3,38	0,15	4,3	47	0							CRV	3,447	0,034	9%	3,13	3,76		47		46	
Other					1	0																	1
Sample B		5,10	0,23	4,5	48							0											48
																							48

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: AKS1/21 - Basic Clinical Chemistry - Serum

Deadline: 29.01.2021

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}									
(15) Cholesterol	[mmol/L]				48							0				48	46	96%					
Samples and groups																							
Sample B		5,10	0,23	4,5	48							0				48	48	100%					
(1) Enzyme method CHOD-PAP		5,10	0,23	4,5	47	0							CRV	5,129	0,051	9%	4,66	5,6	47				
Other					1	0													1				
													1x 99										
(16) Glucose	[mmol/L]				51							0				51	51	100%					
Samples and groups																							
Sample A		6,56	0,18	2,7	51							0		CRV	6,53	0,065	8%	6	7,06	51	51	100%	
(1) GOD photometry		6,65	0,12	1,8	15	0															15		
(3) Method with hexokinase		6,52	0,19	2,8	36	0															36		
Sample B		5,35	0,16	3,0	51							0		CRV	5,467	0,055	8%	5,02	5,91	51	51	100%	
(1) GOD photometry		5,48	0,14	2,6	15	0															15		
(3) Method with hexokinase		5,31	0,14	2,7	36	0															36		
(17) Uric acid	[µmol/L]				49							0				49	49	100%					
Samples and groups																							
Sample A		417	14	3,4	49							0		CRV	415,2	4,2	12%	365	466	49	49	100%	
(2) Enzyme-photomet. m.		417	14	3,4	49	0															49		
Sample B		610	17	2,8	49							0		CRV	612	6,1	12%	538	686	49	49	100%	
(2) Enzyme-photomet. m.		610	17	2,8	49	0															49		
(18) Urea	[mmol/L]				51							0				51	50	98%					
Samples and groups																							
Sample A		18,7	0,66	3,5	51							0		CRV	19,4	0,19	15%	16,4	22,4	51	51	100%	
(1) UV enzymatic m.(GMD)		18,7	0,67	3,6	50	0															50		
Other					1	0															1		
														1x 99									
Sample B		14,9	0,54	3,6	51							0		CRV	15,3	0,15	15%	13	17,6	51	50	98%	
(1) UV enzymatic m.(GMD)		14,9	0,54	3,6	50	0															50		
Other					1	0															1		
														1x 99									
(19) Creatinine	[µmol/L]				51							0				51	50	98%					
Samples and groups																							
Sample A		165	6,5	4,0	51							0		CRV	164,8	1,6	13%	143	187	51	51	100%	
(1) Jaffe		165	7,0	4,2	28	0															28		
(3) Enzyme		165	6,1	3,7	23	0															23		
Sample B		151	8,9	5,9	51							0		CRV	146,6	1,7	13%	127	166	51	50	98%	
(1) Jaffe		155	7,9	5,1	28	0															28		
(3) Enzyme		146	5,1	3,5	23	0															23		
(20) Triacylglycerols	[mmol/L]				48							0				48	48	100%					
Samples and groups																							
Sample A		1,39	0,05	3,7	48							0		CRV	1,369	0,016	15%	1,16	1,58	48	48	100%	
(1) Photometric enzyme (GPO-PAP)		1,39	0,05	3,7	46	0															46		
Other					2	0															2		
														2x 2									
Sample B		1,31	0,05	4,1	48							0		CRV	1,318	0,013	15%	1,12	1,52	48	48	100%	

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: AKS1/21 - Basic Clinical Chemistry - Serum

Deadline: 29.01.2021

Test	[unit]	Comparability					Traceability															
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}								
(20) Triacylglycerols	[mmol/L]				48							0				48	48	100%				
Samples and groups																						
Sample B		1,31	0,05	4,1	48							0	CRV	1,318	0,013	15%	1,12	1,52	48	48	100%	
(1) Photometric enzyme (GPO-PAP)		1,31	0,05	4,2	46	0													46			
Other					2	0													2			
												2x2										
(21) ALP	[µkat/L]				49							0							49	49	100%	
Samples and groups																						
Sample A		4,33	0,51	12	49							0	CRV	4,568	0,10	28%	3,28	5,85	49	49	100%	
(3) IFCC method		4,33	0,51	12	49	0													49			
Sample B		2,59	0,24	9,2	49							0	CRV	2,731	,0080	28%	1,96	3,5	49	49	100%	
(3) IFCC method		2,59	0,24	9,2	49	0													49			
(22) alpha-amylase	[µkat/L]				51							0							51	47	92%	
Samples and groups																						
Sample A		8,00	0,43	5,4	51							0							51	47	92%	
(1) IFCC method		8,00	0,43	5,4	51	0							CRV	8,213	0,22	15%	6,98	9,45	51			
Sample B		8,16	0,49	6,0	51							0							51	47	92%	
(1) IFCC method		8,16	0,49	6,0	51	0							CRV	8,325	0,023	15%	7,07	9,58	51			
(23) AST	[µkat/L]				51							0							51	41	80%	
Samples and groups																						
Sample A		5,39	0,40	7,4	51							0		CRV	5,711	0,13	15%	4,85	6,57	51	46	90%
(1) IFCC method		5,40	0,39	7,3	50	0													50			
Other					1	0													1			
Sample B		3,12	0,27	8,6	51							0	CRV	3,287	0,013	15%	2,79	3,79	51	43	84%	
(1) IFCC method		3,13	0,26	8,3	50	0													50			
Other					1	0													1			
													1x99									
(24) ALT	[µkat/L]				52							0							52	51	98%	
Samples and groups																						
Sample A		2,98	0,12	4,0	52							0		CRV	3,084	0,078	15%	2,62	3,55	52	52	100%
(1) IFCC method		2,98	0,12	4,0	51	0													51			
Other					1	0													1			
Sample B		1,20	0,08	7,2	52							0	CRV	1,222	0,013	15%	1,03	1,41	52	51	98%	
(1) IFCC method		1,20	0,08	7,2	51	0													51			
Other					1	0													1			
(26) CK	[µkat/L]				50							0							50	50	100%	
Samples and groups																						
Sample A		5,32	0,41	7,8	50							0		CRV	5,598	0,17	20%	4,47	6,72	50	50	100%
(1) IFCC method		5,32	0,41	7,8	50	0													50			
Sample B		3,38	0,22	6,6	50							0		CRV	3,469	0,037	20%	2,77	4,17	50	50	100%
(1) IFCC method		3,38	0,22	6,6	50	0													50			

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: AKS1/21 - Basic Clinical Chemistry - Serum

Deadline: 29.01.2021

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(27) gamma-GT					49							0									49	48	98%
Samples and groups	[µkat/L]																						
Sample A		2,47	0,08	3,5	49							0		CRV	2,561	0,065	15%	2,17	2,95		49	48	98%
(1) IFCC method		2,47	0,08	3,5	49	0															49		
Sample B		2,10	0,06	3,2	49							0		CRV	2,175	0,080	15%	1,84	2,51		49	48	98%
(1) IFCC method		2,10	0,06	3,2	49	0															49		
(28) LD					40							0									40	40	100%
Samples and groups	[µkat/L]																						
Sample A		2,78	0,12	4,4	40							0		CRV	2,902	0,067	18%	2,37	3,43		40	40	100%
(3) IFCC method		2,78	0,12	4,4	40	0															40		
Sample B		7,30	0,20	2,7	40							0		CRV	7,378	0,033	18%	6,05	8,71		40	40	100%
(3) IFCC method		7,30	0,20	2,7	40	0															40		
(29) Lipase					27							23	20	87%							0		
Samples and groups	[µkat/L]																						
Sample A		0,929	0,14	15	27							23	21	91%							0		
(0) Not specified; (58) Beckman Coulter (AU)		1,05	0,08	7,8	7	0	CVPG	1,04	0,028	24%	0,79	1,29	7										
(0) Not specified; (60) Roche		0,846	0,07	9,0	13	0	CVPG	0,895	0,011	24%	0,68	1,11	13										
Other					7	0						3											
								1x 0/12, 1x 0/177, 2x 0/178, 3x 0/179															
Sample B		1,72	0,22	12	27							23	21	91%							0		
(0) Not specified; (58) Beckman Coulter (AU)		1,84	0,11	6,1	7	0	CVPG	1,86	0,037	24%	1,41	2,31	7										
(0) Not specified; (60) Roche		1,60	0,18	12	13	0	CVPG	1,72	0,027	24%	1,3	2,14	13										
Other					7	0						3											
								1x 0/12, 1x 0/177, 2x 0/178, 3x 0/179															
(30) Cholinesterase					20							20	19	95%							0		
Samples and groups	[µkat/L]																						
Sample A		119	5,9	5,0	20							20	19	95%							0		
(1) Standard method		119	5,9	5,0	20	0	CVP	121	1,4	12%	106	136	20										
Sample B		168	8,5	5,1	20							20	19	95%							0		
(1) Standard method		168	8,5	5,1	20	0	CVP	170	2,1	12%	149	191	20										
(31) Albumin (elpho)					9							9	9	100%							0		
Samples and groups	[-]																						
Sample A		0,643	0,03	6,0	9		CVP	0,645	0,012	15%	0,548	0,742	9	9	100%					0			
(0) Not specified		0,643	0,03	6,0	9	0						9											
Sample B		0,615	0,06	11	9		CVP	0,634	0,016	15%	0,538	0,73	9	9	100%					0			
(0) Not specified		0,615	0,06	11	9	0						9											
(32) gamma-globuline (elpho)					9							9	8	89%							0		
Samples and groups	[-]																						
Sample A		0,126	0,01	11	9		CVP	0,123	0,0045	30%	0,086	0,16	9	9	100%					0			
(0) Not specified		0,126	0,01	11	9	0						9											
Sample B		0,125	0,01	15	9		CVP	0,124	0,0049	30%	0,086	0,162	9	8	89%					0			
(0) Not specified		0,125	0,01	15	9	0						9											

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: AKS1/21 - Basic Clinical Chemistry - Serum

Deadline: 29.01.2021

Test	[unit]	Comparability					Traceability																	
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
(35) alpha-amylase pancreatic					20							20	20	100%							0			
Samples and groups	[µkat/L]																							
Sample A		7,19	0,22	3,1	20	CVP	7,24	0,080	18%	5,93	8,55	20	20	100%							0			
(1) With IFCC calibration		7,19	0,22	3,1	20	0						20												
Sample B		7,15	0,21	2,9	20	CVP	7,21	0,078	18%	5,91	8,51	20	20	100%							0			
(1) With IFCC calibration		7,15	0,21	2,9	20	0						20												
(36) Calcium ionised					6							6	5	83%							0			
Samples and groups	[mmol/L]																							
Sample A		1,32	0,07	5,6	6	CVP	1,32	0,019	10%	1,18	1,46	6	5	83%							0			
(2) Direct ISE		1,32	0,07	5,6	6	0						6												
Sample B		1,67	0,03	2,2	6	CVP	1,68	0,016	10%	1,51	1,85	6	5	83%							0			
(2) Direct ISE		1,67	0,03	2,2	6	0						6												

st_kn_np

End of report

Printed: 04.02.2021